Barclays
BIB icon

Barclays’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Barclays’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,000
Closed -$90K – 6828
2015
Q2 		$90K Buy
+1,000
New +$86K ﹤0.01% 4740

Other funds holding BIB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return
WSTAM
Wilbanks Smith & Thomas Asset Management Norfolk, Virginia $3.57B AUM 21.11% 1-Year Est. Return
BHA
Beech Hill Advisors New York $200M AUM 25.74% 1-Year Est. Return

Barclays's BIB Position: Q3 2015 in Review

Barclays sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2015, closing a stake of 1,000 shares — an estimated $90K sold.

Barclays first reported a position in BIB in Q2 2015 and held it in 1 quarter. The position peaked at $90K in Q2 2015. 24 funds tracked by Wall St. Rank hold BIB as of Q3 2015.

  • Barclays reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2015 after selling out during the quarter.
  • Barclays sold 1,000 ProShares Ultra NASDAQ Biotechnology shares in Q3 2015, an estimated $90K.
  • Barclays first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2015 and held it in 1 quarter.
  • Barclays's ProShares Ultra NASDAQ Biotechnology position peaked at $90K in Q2 2015.
  • 24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2015.

Based on Barclays's 13F filing for Q3 2015, filed 13 Nov 2015.